Hearn Cho is an Oncology physician. OpenAlex indexes 394 publications with 6,448 citations (h-index 37); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 100296030
Telephone
212-241-6756Registry record last updated 25 Feb 2019.
Clinical trials
- Horizon Two: HR NDMM (MMRC-100)
Sponsor: Multiple Myeloma Research Consortium
- MMRC Horizon One: RRMM (MMRC-099)
Sponsor: Multiple Myeloma Research Consortium
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Sponsor: Multiple Myeloma Research Consortium
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sekisui Diagnostics LLCProgram year20251 payment
- Janssen Biotech, Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
67.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor67.8%Acyclovir100%Part D≥14 patientsNervous system
18.9%Gabapentinoids18.9%Gabapentin100%Part D<11 patientsSensory organs
13.3%Corticosteroid13.3%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2006–2016 per NIH RePORTER. The latest:
- Novel therapeutic strategies targeting conformational plasticity of type I MAGE
Icahn School of Medicine at Mount Sinai
FY2016$182,588R21CA191898 - Novel therapeutic strategies targeting conformational plasticity of type I MAGE
Icahn School of Medicine at Mount Sinai
FY2015$223,096R21CA191898 - Type 1 MAGE vaccine immunotherapy for multiple myeloma
New York University School of Medicine
FY2010$159,624K01CA115917
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”